FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
Friday, the FDA approved Pfizer Inc's (NYSE:PFE) Beqvez (fidanacogene elaparvovec-dzkt) for moderate to severe hemophilia B in adult patients who currently use factor IX (FIX) prophylaxis therapy or h
BenzingaApr 26 14:30 ET
Travere, CSL Win Conditional Nod for Kidney Disease Therapy in EU
Seeking AlphaApr 24 08:31 ET
CureVac Posts Early Efficacy Results for GSK-partnered Flu Shot
Seeking AlphaApr 4 08:20 ET
Akebia Stock Jumps as FDA Clears Renal Anemia Therapy
Seeking AlphaMar 28 05:42 ET
Kyowa Kirin's Rare Disease Therapy Becomes World's Most Expensive Drug
Seeking AlphaMar 20 12:11 ET
Ferinject Approved by Health Canada for the Treatment of Iron Deficiency Anemia in Adult...
Stockhouse Mar 19 07:00 ET
CSL Ltd's Dividend Analysis
Yahoo FinanceMar 11 07:01 ET
CSL Goes Ex Dividend Tomorrow
Seeking AlphaMar 7 09:19 ET
'Tripledemic' Burden Lower This Winter Despite COVID Impact: Airfinity
Seeking AlphaFeb 27 13:44 ET
Express News | Travere Therapeutics And CSL Vifor Announced That The European Medicines Agency's CHMP Has Recommended Approval Of Sparsentan For Primary IgA Nephropathy With A Urine Protein Excretion >1.0 G/Day; European Commission Decision Is Expected In Q2 2024
Moomoo 24/7Feb 23 07:07 ET
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe Positive CHMP opinion is
GlobeNewswireFeb 23 07:05 ET
Travere Therapeutics Gains as EU Backs Kidney Disease Therapy
Seeking AlphaFeb 23 07:05 ET
CSL LTD SPON ADR EACH REPR 0.5 ORD To Go Ex-Dividend On March 11th, 2024 With 0.595 USD Dividend Per Share
February 15th - $CSL LTD SPON ADR EACH REPR 0.5 ORD(CSLLY.US)$ is trading ex-dividend on March 11th, 2024. Shareholders of record on March 12th, 2024 will receive 0.595 USD dividend per share. The
moomoo NewsFeb 14 19:40 ET
Earnings Call Summary | CSL LTD SPON ADR EACH REPR 0.5 ORD(CSLLY.US) Q2 2024 Earnings Conference
The following is a summary of the CSL Ltd (CSLLY) Q2 2024 Earnings Call Transcript:Financial Performance:CSL reported revenue of $8.1 billion, an increase of 11% at constant currency.CSL's NPATA was $
moomoo AIFeb 13 01:08 ET · Conference Call
CSL Limited Falls After Phase 3 Setback for Key Trial
Seeking AlphaFeb 12 13:53 ET
CSL Announces Top-line Results From the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety...
Stockhouse Feb 11 17:47 ET
Notable Earnings After Monday's Close
Seeking AlphaFeb 10 17:35 ET
Masking Returns to Some U.S. Hospitals Amid Rising COVID, Flu Cases
Seeking AlphaJan 4 13:51 ET
Pfizer Wins Canada Approval for Hemophilia B Gene Therapy
Seeking AlphaJan 3 10:19 ET
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation MRNA Vaccine Booster
Data follow approval of the world's first Self-Amplifying messenger RNA (sa-mRNA) COVID-19 Vaccine for Adults by Japan Ministry of Health, Labor and Welfare.
Arcturus TherapeuticsDec 21, 2023 08:00 ET
No Data
No Data